News in English
Enter any phrase or word you would like to search for and click .
PostNews: Interim Report
Interim Report for the second quarter
For the first time, sales during the past 12 months reached 5 MSEK. Since our previous report, much effort has gone into implementing the ambitious market expansion made possible by the capital acquisition this summer.
Learn more …
PostNews: Press Release
Lund University and PHI partner to develop novel 3D cell culturing methods for immunotherapy research
Based on PHI’s current HoloMonitor technology, the Department of Immunotechnology at Lund University and Phase Holographic Imaging (PHI) recently agreed to jointly develop novel 3-dimensional cell culturing methods to meet the urgent need for such methods.
Learn more …
PostNews: Press Release
Rights issue enables market expansion
The Board of Directors and the CEO of Phase Holographic Imaging PHI AB (publ), corporate identity number 556542-7811, hereby submit Interim Report 1 for the fiscal year 2018/19.
Learn more …
PostPress Release
Kallelse till årsstämma i Phase Holographic Imaging PHI (publ)
Aktieägarna i Phase Holographic Imaging PHI AB (publ), 556542-7811, kallas härmed till årsstämma onsdagen den 26 september 2018 kl. 17.00 i bolagets lokaler, Scheelevägen 22 i Lund.
Learn more …
PostNews
New CEO commentary: “Understanding Skin Cancer”
PHI’s CEO and founder Peter Egelberg comments the latest research results by the scientists at the PHI/UCSF Holographic Imaging Cytometry Center of Excellence.
Learn more …
PostNews
Scientists at UCSF-PHI Center of Excellence map the genetic progression of invasive skin cancer
Utilizing precision genetic engineering and PHI’s HoloMonitor technology, scientists at University of California, San Francisco, have for the first time been able to monitor and map how mutations break down the genetic protection against skin cancer.
Learn more …